Background: We report the efficacy and safety of E‐52862—a selective, sigma‐1 receptor antagonist—from phase 2, randomized, proof‐of‐concept studies in patients with moderate‐to‐severe, neuropathic, chronic postsurgical pain (CPSP) and painful diabetic neuropathy (PDN).Methods: Adult patients (CPSP [N = 116]; PDN [N = 163]) were randomized at a 1:1 ratio to 4 weeks of treatment with E‐52862 (CPSP [n = 55]; PDN [n = 85]) or placebo (CPSP [n = 61]; PDN [n = 78]) orally once daily. Pain intensity scores were measured using a numerical pain rating scale from 0 (no pain) to 10 (worst pain imaginable). The primary analysis population comprised patients who received study drug with ≥1 baseline and on‐treatment observation (full analysis set).Results: In CPSP, mean baseline average pain was 6.2 for E‐52862 vs. 6.5 for placebo. Week 4 mean change from baseline (CFB) for average pain was −1.6 for E‐52862 vs. –0.9 for placebo (least squares mean difference [LSMD]: −0.9; p = 0.029). In PDN, mean baseline average pain was 5.3 for E‐52862 vs. 5.4 for placebo. Week 4 mean CFB for average pain was −2.2 for E‐52862 vs. –2.1 for placebo (LSMD: –0.1; p = 0.766). Treatment‐emergent adverse events (TEAEs) were reported in 90.9% of E‐52862‐treated patients vs. 76.7% of placebo‐treated patients in CPSP and 34.1% vs. 26.9% in PDN. Serious TEAEs occurred in CPSP only: E‐52862: 5.5%; placebo: 6.7%.Conclusions: E‐52862 demonstrated superior relief of CPSP vs. placebo after 4 weeks. Reductions in pain intensity were seen in PDN with E‐52862; high placebo response rates may have prevented differentiation between treatments. E‐52862 had acceptable tolerability in both populations.Significance Statement: These proof‐of‐concept studies validate the mode of action of E‐52862, a selective sigma‐1 receptor antagonist. In CPSP, E‐52862 resulted in clinically meaningful pain relief. In PDN, reductions in pain intensity were seen with E‐52862; high placebo response rates may have prevented differentiation between E‐52862 and placebo. These findings are clinically relevant given that neuropathic pain is highly incapacitating, lacking effective treatments and representing a significant unmet medical need, and support further development of sigma‐1 receptor antagonists for peripheral neuropathic pain.
Purpose: The objectives of this project were to assess the current situation and management of cancer-related neuropathic pain (CRNP) in Spain and to provide specific recommendations for the assessment, diagnosis and treatment of CRNP using a Delphi methodology. Methods: This was a qualitative study that followed a Delphi methodology using a questionnaire with 56 statements that were grouped into 5 areas related to CRNP: prevalence and impact, pathophysiology, assessment and diagnosis, specific syndromes, treatment, and multidisciplinary approach. Based on the responses, the scientific committee prepared an algorithm and a recommended pathway for the management of CRNP. Results: Seventy-nine physicians attended the meeting and completed the questionnaire. Consensus was reached for all statements relating to the prevalence and impact of CRNP. However, the perceptions of specialists from palliative care of the frequency and impact of CRNP differed from those of other specialists. A high degree of consensus was reached for all statements concerning the assessment and diagnosis of CRNP. Regarding specific syndromes, the only statement with a lack of consensus was that on the frequency of NP in patients undergoing radiotherapy. There were some disagreements regarding the multidisciplinary approach and referral criteria for the management of NP. Conclusion: Our results show a large degree of agreement on the assessment, diagnosis and treatment of cancer-related neuropathic pain among the specialists involved in its management. There were, however, some disagreements regarding the multidisciplinary approach and referral criteria for the management of neuropathic pain.
Background: Ziconotide and morphine are intrathecal (IT) drugs approved by the FDA and EMA for the treatment of chronic pain. The aim of this study was to determine whether opioid rescue can be achieved by gradually increasing doses of ziconotide, and to establish a practical protocol for its implementation. Methods: Five patients unresponsive to IT morphine due to lack of efficacy or adverse events such as endocrine dysfunction, constipation and tolerance were selected. All had refractory, neuropathic or mixed pain. Ziconotide was gradually introduced while maintaining or reducing morphine doses in proportion to the ziconotide titration. Dose adjustments were made every 2 weeks, with a weekly ziconotide increase of 0.5 μg. Results: Of the five patients, three were female and two were male, with ages ranging from 53 to 75 years. Two had cancer (one with colon cancer and one with osteosarcoma), two had persistent spinal pain syndrome type 2, and one had spastic paraparesis. After 6 weeks of ziconotide treatment, all individuals showed a substantial reduction in daily morphine dosage (from 10 to 5.5 mg/day), which was associated with improved control of adverse events. Similarly, notable reductions were observed in pain intensity (from 8.0 to 2.5, measured by VAS) and neuropathic symptoms (from 6.0 to 2.0, measured by DN4). The most frequently improved neuropathic symptoms included tingling (4 patients), hypoesthesia to touch (3 patients), and pain evoked by brushing (3 patients). The duration of the rescue protocol ranged from 5 to 11 weeks. Conclusion: Intrathecal opioid rescue with ziconotide emerges as a viable therapeutic option for patients with refractory pain and a neuropathic component, or for those who develop adverse events associated with IT morphine. Low doses and slow titration of ziconotide may help minimize adverse events while maintaining analgesic benefit. Plain Language Summary: Ziconotide and morphine are two medications used to treat chronic pain by delivering the drugs directly into the spinal fluid. While both are approved by health authorities like the FDA and EMA, some patients have problems with morphine, such as side effects or not working well enough. This study looked at whether ziconotide could help these patients by reducing the need for morphine and controlling their pain more effectively. Five patients who did not respond well to morphine or had side effects were included in the study. The researchers gradually increased the dose of ziconotide while either keeping the morphine dose the same or reducing it. The patients’ pain and side effects were carefully monitored. The results showed that all the patients were able to significantly reduce their morphine doses, which helped to reduce unwanted side effects. At the same time, their pain levels decreased, and their neuropathic symptoms (pain caused by nerve damage) improved. The rescue period lasted from 5 to 11 weeks. In conclusion, ziconotide may be a good alternative for people who have problems with morphine or have pain that does not respond to traditional treatments. Using low doses of ziconotide and increasing them slowly helps to minimize side effects while maintaining analgesic benefit.